BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Signase
Signase developed novel, small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. It was spun out of the M. D. Anderson Cancer Center. The company’s assets were acquired by Systems Medicine Inc. in 2005.
Signase
Houston, TX
